Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPG302 in mild-to-moderate Alzheimer's disease
NCT06833281Phase 2Terminated
- Sponsor
- Spinogenix
- Start
- Mar 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tazbentetol in Alzheimer's disease (AD), sponsored by Spinogenix. Started Mar 2025; status: terminated.
02
Drugs
tazbentetol
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06833281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06833281.